A single injection engineered to last a lifetime

Clinical Trials


HMR-1001 is a Phase 1 FDA approved clinical trial that is closed to enrollment and inactive as of January 2020.  HMR-1001 evaluated 17 eyes of 17 subjects with advanced dry AMD and geographic atrophy who received a single intravitreal dose of HMR59.  Information on HMR-1001 is available here:

View Trial


HMR-1002 is a Phase 1 FDA approved trial for the treatment of 25 subjects diagnosed with new onset wet AMD who have never received treatment in the affected eye.  HMR-1002 enrolled subjects at Ophthalmic Consultants of Boston and Vitreo-Retinal Associates in Worcester, MA.  All patients who met enrollment criteria were treated with a single intravitreal injection of an anti-VEGF medication followed 7 days later by an intravitreal injection of HMR59.  Patients were followed monthly and treated with anti-VEGF injections as needed through month 12 followed by a month 24 visit to evaluate long-term safety.  Information on HMR-1002 is available here:

View Trial